AntiDepressants, Psychiatric Drugs, Psychiatrists and Big Pharma

Psychiatrists: the drug pushers

Psychiatrists: the drug pushers
Psychiatrists: the drug pushers, by @wself

Is the current epidemic of depression and hyperactivity the result of disease-mongering by the psychiatric profession and big pharma?

Does psychiatry have any credibility left at all?

The question is asked by Novelist, Journalist Will Self, who ends his post saying:

Sooner or later we will all have to wake up, smell the snake oil, and realise that while medical science may bring incalculable benefit to us, medical pseudo-science remains just as capable of advance. After all, one of the drugs that Irving Kirsch’s meta‑analysis of antidepressant trials revealed as being just as efficacious as the SSRIs was … heroin “.

August 2013 FACS aware Peaceful Protest at London MHRA Building

FACSaware aims to raising global awareness of Fetal Anti Convulsant Syndromes and other teratogen-related issues

FACT was set up in 2011 to campaign for responsibility from the government and drug company
The #FACSaware Peaceful Protest at London #MHRA Building

FACSaware aims to raising global awareness of Fetal Anti Convulsant Syndromes and other Teratogen related syndromes. The Fetal AntiConvulsant Trust (F.A.C.T.) was set up in 2011 to campaign for responsibility from the government and drug company.

  • Watch the video from the UK Parlement Private Members Debate Fetal anti-convulsant syndrome with Anas Sarwar
  • Visit Jo Cozens blog and Twitter
  • Visit the FACS website and Twitter
  • The F.A.C.T. open group on Facebook

Breast Cancer Screening in Women exposed in Utero to DiEthylStilbestrol

The majority of DES-exposed women do not perform monthly breast-self examinations

DES Follow-up Study Summary

National Cancer Inst logo image
The majority of DES-exposed women do not perform monthly breast-self examinations.

The purpose of this paper was to determine if women exposed in utero to Diethylstilbestrol (DES) are more likely than unexposed women to receive recommended or additional breast cancer screening examinations.

Data from the study cohort were used to assess the degree of recommended compliance of breast cancer screenings was found in 3,140 DES exposed and 826 unexposed women. Participants were enrolled at four sites: Houston, Boston, Rochester, and Los Angeles. The data from the mailed questionnaires that included the reported frequency from 1990 through 1994 of breast-self examinations (BSEs), clinical breast examinations (CBEs), and mammograms was analyzed.

The results showed that the DES-exposed women exceeded annual recommendations for CBEs among women without a history of benign breast disease compared with unexposed women. There were no other statistically significant differences between exposed and unexposed women who reported performing BSEs, CBEs (less than 40 years of age), and mammographies, regardless of benign breast disease history.

Although this study showed that the majority of DES-exposed women receive breast cancer screenings at least at recommended intervals, it also showed that over two thirds do not perform monthly BSEs. It is recommended that Future efforts should be focused on further educating this and other at-risk populations through mailed reminders and during patient consultations on the benefits of screening examinations.

2009 Study Abstract

Purpose:
To determine if women exposed in utero to diethylstilbestrol (DES) are more likely than unexposed women to receive recommended or additional breast cancer screening examinations.

Methods:
1994 Diethylstilbestrol-Adenosis (DESAD) cohort data are used to assess the degree of recommended compliance of breast cancer screenings found in 3140 DES-exposed and 826 unexposed women. Participants were enrolled at four sites: Houston, Boston, Rochester, and Los Angeles. Logistic regression modeling was used to analyze mailed questionnaire data that included reported frequency over the preceding 5 years (1990-1994) of breast-self examinations (BSEs), clinical breast examinations (CBEs), and mammograms.

Results:
DES-exposed women exceeded annual recommendations for CBEs (aOR 2.20, 95% CI, 1.04-4.67) among women without a history of benign breast disease (BBD) compared with unexposed women. There were no other statistically significant differences between exposed and unexposed women who reported performing BSEs, CBEs (<40 years of age), and mammographies, regardless of BBD history.

Conclusions:
The majority of DES-exposed women receive breast cancer screenings at least at recommended intervals, but over two thirds do not perform monthly BSEs. Future efforts should be focused on further educating this and other at-risk populations through mailed reminders and during patient consultations on the benefits of screening examinations.

Sources

  • Breast cancer screening in women exposed in utero to diethylstilbestrol,NCBI, PMID: 19361323, 2009 Apr;18(4):547-52. doi: 10.1089/jwh.2007.0580. Full text PMC2857514.
  • NCI, DES Follow-up Study Published Papers.
Related posts
More DES DiEthylStilbestrol Resources

IVF linked to Risk of Intellectual Disabilities

Autism and mental retardation among offspring born after in vitro fertilization

IVF, Autism Not Linked, But Study Finds Risk Of Intellectual Disabilities
Continued study of the implications of ovarian stimulation, embryo culture, and multiple embryo transfer is required

A study of more than 2.5 million children found no link between in vitro fertilization (IVF) and autism, but a slight increase in risk for mental retardation, or intellectual disabilities. Certain treatments used to specifically target male factor infertility – in particular, intracytoplasmic sperm injection, or ICSI – carried higher risks, but the overall risk of children being born with intellectual disabilities, defined as an IQ as under 70, was quite small. ”

Abstract

IMPORTANCE
Between 1978 and 2010, approximately 5 million infants were born after in vitro fertilization (IVF) treatments. Yet limited information on neurodevelopment after IVF exists, especially after the first year of life.

OBJECTIVE
To examine the association between use of any IVF and different IVF procedures and the risk of autistic disorder and mental retardation in the offspring.

DESIGN, SETTING, AND PARTICIPANTS
A population-based, prospective cohort study using Swedish national health registers. Offspring born between 1982 and 2007 were followed up for a clinical diagnosis of autistic disorder or mental retardation until December 31, 2009. The exposure of interest was IVF, categorized according to whether intracytoplasmic sperm injection (ICSI) for male infertility was used and whether embryos were fresh or frozen. For ICSI, whether sperm were ejaculated or surgically extracted was also considered.

MAIN OUTCOMES AND MEASURES
Relative risks (RRs) for autistic disorder and mental retardation and rates per 100,000 person-years, comparing spontaneously conceived offspring with those born after an IVF procedure and comparing 5 IVF procedures used in Sweden vs IVF without ICSI with fresh embryo transfer, the most common treatment. We also analyzed the subgroup restricted to singletons.

RESULTS
Of the more than 2.5 million infants born, 30,959 (1.2%) were conceived by IVF and were followed up for a mean 10 (SD, 6) years. Overall, 103 of 6959 children (1.5%) with autistic disorder and 180 of 15,830 (1.1%) with mental retardation were conceived by IVF. The RR for autistic disorder after any procedure compared with spontaneous conception was 1.14 (95% CI, 0.94-1.39; 19.0 vs 15.6 per 100,000 person-years). The RR for mental retardation was 1.18 (95% CI, 1.01-1.36; 46.3 vs 39.8 per 100,000 person-years). For both outcomes, there was no statistically significant association when restricting analysis to singletons. Compared with IVF without ICSI with fresh embryo transfer, there were statistically significantly increased risks of autistic disorder following ICSI using surgically extracted sperm and fresh embryos (RR, 4.60 [95% CI, 2.14-9.88]; 135.7 vs 29.3 per 100,000 person-years); for mental retardation following ICSI using surgically extracted sperm and fresh embryos (RR, 2.35 [95% CI, 1.01-5.45]; 144.1 vs 60.8 per 100,000 person-years); and following ICSI using ejaculated sperm and fresh embryos (RR, 1.47 [95% CI, 1.03-2.09]; 90.6 vs 60.8 per 100,000 person-years). When restricting the analysis to singletons, the risks of autistic disorder associated with ICSI using surgically extracted sperm were not statistically significant, but the risks associated with ICSI using frozen embryos were significant for mental retardation (with frozen embryos, RR, 2.36 [95% CI, 1.04-5.36], 118.4 vs 50.6 per 100,000 person-years]; with fresh embryos, RR, 1.60 [95% CI, 1.00-2.57], 80.0 vs 50.6 per 100,000 person-years).

CONCLUSIONS AND RELEVANCE
Compared with spontaneous conception, IVF treatment overall was not associated with autistic disorder but was associated with a small but statistically significantly increased risk of mental retardation. For specific procedures, IVF with ICSI for paternal infertility was associated with a small increase in the RR for autistic disorder and mental retardation compared with IVF without ICSI. The prevalence of these disorders was low, and the increase in absolute risk associated with IVF was small.

Related posts:

Parental Depression, maternal AntiDepressant during Pregnancy, Autism Spectrum Disorders Risk

AntiDepressant use during Pregnancy and Childhood Autism Spectrum Disorders

Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study
In utero exposure to SSRIs antidepressants is associated with an increased risk of autism spectrum disorders

Objective:
To study the association between parental depression and maternal antidepressant use during pregnancy with autism spectrum disorders in offspring.

Design:
Population based nested case-control study.

Setting:
Stockholm County, Sweden, 2001-07.

Participants:
4429 cases of autism spectrum disorder (1828 with and 2601 without intellectual disability) and 43 277 age and sex matched controls in the full sample (1679 cases of autism spectrum disorder and 16 845 controls with data on maternal antidepressant use nested within a cohort (n=589 114) of young people aged 0-17 years.

Main outcome measure:
A diagnosis of autism spectrum disorder, with or without intellectual disability.

Exposures:
Parental depression and other characteristics prospectively recorded in administrative registers before the birth of the child. Maternal antidepressant use, recorded at the first antenatal interview, was available for children born from 1995 onwards.

Results:
A history of maternal (adjusted odds ratio 1.49, 95% confidence interval 1.08 to 2.08) but not paternal depression was associated with an increased risk of autism spectrum disorders in offspring. In the subsample with available data on drugs, this association was confined to women reporting antidepressant use during pregnancy (3.34, 1.50 to 7.47, P=0.003), irrespective of whether selective serotonin reuptake inhibitors (SSRIs) or non-selective monoamine reuptake inhibitors were reported. All associations were higher in cases of autism without intellectual disability, there being no evidence of an increased risk of autism with intellectual disability. Assuming an unconfounded, causal association, antidepressant use during pregnancy explained 0.6% of the cases of autism spectrum disorder.

Conclusions:
In utero exposure to both SSRIs and non-selective monoamine reuptake inhibitors (tricyclic antidepressants) was associated with an increased risk of autism spectrum disorders, particularly without intellectual disability. Whether this association is causal or reflects the risk of autism with severe depression during pregnancy requires further research. However, assuming causality, antidepressant use during pregnancy is unlikely to have contributed significantly towards the dramatic increase in observed prevalence of autism spectrum disorders as it explained less than 1% of cases.

Sources: Read the full article Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study
NCBI, Apr 2013 – Full PDF.

Will the proposed Chemical Safety Improvement Act undercut State Laws that protect Consumers?

A retreat on chemical safety?

A retreat on chemical safety
Only 200 of the 85,000 industrial chemicals in use, not including pesticides, have been tested or regulated

Six years ago, a California environmental group learned that certain baby bibs were made with potentially dangerous amounts of lead. A lawsuit followed, asserting that the bibs violated California’s sweeping environmental toxins law. As a result, Wal-Mart and Toys R Us pulled the bibs from their stores, not just in California but around the country. This is just one of many cases in which California’s strong environmental standards have protected health nationwide.

But such protections could be undermined by a bill in Congress that is intended to replace the ineffectual, decades-old federal law governing industrial chemicals. In its current state, the bill would do more to harm public health than to protect it. ”

Read A retreat on chemical safety
by The Times editorial board; 2 Aug 2013.

Cancer Risk in Women prenatally exposed to DiEthylStilbestrol

30% increase in cancer risk for DES-exposed females

2007 Study Abstract

National Cancer Inst logo image
Comparing exposed with unexposed women within the 2007 study, there was about a 30% increase in cancer risk.

Prenatal Diethylstilbestrol [DES] exposure is associated with higher risks of clear cell adenocarcinoma [CCA], and breast cancer in older women. Whether the overall risk of being diagnosed with any cancer is also elevated is unclear.

A total of 143 exposed women and 49 unexposed women in the DES Combined Cohort Follow-up Study were diagnosed with cancer as of 2001.

Compared with breast cancer rates in the general US population, there was no overall higher risk among DES exposed women. Comparing exposed with unexposed women within the study, there was about a 30% increase in cancer risk but this finding could be due to chance. As reported in a previous article (Palmer 2006), breast cancer risk was elevated but only among women over 40 years of age. Exposed women had a risk of CCA that was nearly 40% higher than the general population, however; the incidence of CCA decreased substantially after age 25 compared with women 20 to 24 years old. Excluding CCA and breast cancer, the higher risk of cancer among the DES exposed women was about 20%, a result that could be due to chance. DES was not associated with higher risks of either endometrial or ovarian cancer. These data suggest that the DES associated increase in CCA rates remains elevated through the reproductive years. There was no consistent evidence of a higher risk for cancers other than CCA, and breast in older women.

Given that the population is still young, continued follow-up is necessary to assess the overall cancer risk associated with prenatal DES exposure.

Sources

More DES DiEthylStilbestrol Resources

Sunshine Act in Today’s Pharma Forecast as Mandate takes Effect

New efforts to reveal the ties between doctors and drug firms

Sunshine Act in today's pharma forecast as mandate takes effect
New efforts to reveal the ties between doctors and drug firms

The earnings picture may be cloudy today in the drug business, but sun is shining in from another quarter. Today is the first day of data-gathering for the newly implemented Physician Payments Sunshine Act.

Read : Sunshine Act in today’s pharma forecast as mandate takes effect
by FiercePharma
1 Aug 2013.

Related post: Will the US Sunshine Law help track Ties between Doctors and Drug Companies in America?

Bisphenol-A BPA and the Great Divide

A Review of Controversies in the Endocrine Disruptors Field

Bisphenol-A and the Great Divide: A Review of Controversies in the Field of Endocrine Disruption
The data collected thus far in the field of environmental toxicology are sufficiently robust to raise concerns about the potentially deleterious impact of endocrine-disrupting chemicals on human development.

In 1991, a group of 21 scientists gathered at the Wingspread Conference Center to discuss evidence of developmental alterations observed in wildlife populations after chemical exposures. There, the term “endocrine disruptor” was agreed upon to describe a class of chemicals including those that act as agonists and antagonists of the estrogen receptors (ERs), androgen receptor, thyroid hormone receptor, and others. This definition has since evolved, and the field has grown to encompass hundreds of chemicals. Despite significant advances in the study of endocrine disruptors, several controversies have sprung up and continue, including the debate over the existence of nonmonotonic dose response curves, the mechanisms of low-dose effects, and the importance of considering critical periods of exposure in experimental design. One chemical found ubiquitously in our environment, bisphenol-A (BPA), has received a tremendous amount of attention from research scientists, government panels, and the popular press.

In their review, The Endocrine Society has covered the above-mentioned controversies plus six additional issues that have divided scientists in the field of BPA research, namely:

  1. mechanisms of BPA action
  2. levels of human exposure
  3. routes of human exposure
  4. pharmacokinetic models of BPA metabolism
  5. effects of BPA on exposed animals
  6. links between BPA and cancer

Understanding these topics is essential for educating the public and medical professionals about potential risks associated with developmental exposure to BPA and other endocrine disruptors, the design of rigorously researched programs using both epidemiological and animal studies, and ultimately the development of a sound public health policy.

Will Proton Beam Cancer Therapy be available in the UK from 2018?

Special Cancer Therapy, Previously Only Available Abroad, Comes To The UK

Special Cancer Therapy, Previously Only Available Abroad, Comes To The UK
Proton beam treatment is also suitable for complex childhood cancers

Cancer patients who currently travel abroad for a special type of radiotherapy will be able to get it in the UK from 2018. Public health minister Anna Soubry said £250 million of Government funding is being committed to hospitals in Manchester and London to deliver proton beam therapy. This type of cancer treatment targets tumours more precisely, causing less damage to surrounding tissue and fewer side-effects.

Read Special Cancer Therapy, Previously Only Available Abroad, Comes To The UK, Huffington Post, 01/08/2013.